SAA Level and SAA/Lipoxin A4 Ratio
Conditions
Brief summary
Serum amlyoid A (SAA) was shown to act as biomarker for exacerbation of chronic obstructive pulmonary disease (AE-COPD). It seems that SAA triggers chronic inflammation by binding to ALX/PFR2 receptor. In contrast, lipoxin A4 seems to inhibit the inflammatory processes by binding to ALX/PFR2 receptor. A small trial has already demonstrated an imbalance between SAA and lipoxin A4 during AE-COPD. This study evaluates SAA level and SAA/lipoxin A4 ratio in patients with stable COPD and AE-COPD.
Detailed description
Patient enrolment and data aquisition is to be carried out on a prospective basis. It is planned to enrol 40 patients with stable COPD and 40 patients with AE-COPD. All patients will undergo blood sampling inlcuding SAA and Lipoxin A4.
Interventions
None listed
Sponsors
Heidelberg University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with COPD GOLD 3-4 confirmed by anamnesis and pulmonary function test * Patient has provided written informed consent
Exclusion criteria
* other reasons for worsening of symptoms (cough, dyspnea): e.g. pneumothorax, pneumonia, pulmonary embolism, myocardial infarction. * malignant disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SAA | time of exacerbation/hospitalisation, an average of 3 days | SAA level in stable COPD and COPD exacerbation |
| SAA/lipoxin A4 ratio | time of exacerbation/hospitalisation, an average of 3 days | SAA/lipoxin A4 ratio in stable COPD and COPD exacerbation |
Countries
Germany
Contacts
Primary ContactDaniela Gompelmann, MD
Outcome results
None listed